CT Scans May Increase The Risk Of Brain Cancer

JOURNAL OF THE NATIONAL CANCER INSTITUTE | July 18, 2018

article image
A new study in the Journal of the National Cancer Institute suggests that CT scans, commonly used in medical imaging, may increase the risk of brain tumors. The use of computed tomography (CT) scans has increased dramatically over the last two decades. CT scans greatly improve diagnostic capabilities (which improve clinical outcomes) but they deliver higher radiation doses than other tests. Therefore, radiation protection is a concern, especially among children, who may receive higher radiation doses, are more susceptible to radiation-related malignancies than adults and have more time to show effects from the potential risk.

Spotlight

Wallace Pharmaceuticals (DC)

The Wallace Group is a privately owned Pharmaceutical & Biotechnology Group headquartered in Goa, India. Incorporated in the late 1960s as a joint venture with Carter Wallace Inc. and Menezes family, the Wallace Group is primarily engaged in the manufacture and marketing of formulation products in India as well as abroad. The Group comprises Wallace Pharmaceuticals, Indi pharma and Goodwin Biotechnology Inc. The Wallace Group employs over 2300 personnel with offices and facilities in several key locations in India and around the world. The Wallace Group comprises of Wallace Pharmaceuticals, Wallace Laboratories, Indi Pharma, Goodwin Bio Tech & Trusts.

OTHER ARTICLES

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | March 20, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

Roche Prepares to Launch COVID-19 Antibody Test System

Article | April 17, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Artificial intelligence in pharma: utilising a valuable resource

Article | March 11, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

Top Specialty Pharmacy Therapy Areas

Article | March 16, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

Spotlight

Wallace Pharmaceuticals (DC)

The Wallace Group is a privately owned Pharmaceutical & Biotechnology Group headquartered in Goa, India. Incorporated in the late 1960s as a joint venture with Carter Wallace Inc. and Menezes family, the Wallace Group is primarily engaged in the manufacture and marketing of formulation products in India as well as abroad. The Group comprises Wallace Pharmaceuticals, Indi pharma and Goodwin Biotechnology Inc. The Wallace Group employs over 2300 personnel with offices and facilities in several key locations in India and around the world. The Wallace Group comprises of Wallace Pharmaceuticals, Wallace Laboratories, Indi Pharma, Goodwin Bio Tech & Trusts.

Events